Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A pharmaceutical composition for treating cardiovascular diseases

A composition and cardiovascular technology, applied in the field of medicine, can solve problems such as limited value, and achieve the effects of high safety and reliable efficacy

Active Publication Date: 2015-05-06
KPC PHARM INC
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The medical community has realized that, due to the complexity of the mechanism of ischemia-reperfusion injury, the value of drugs for the treatment of myocardial ischemia with a single mechanism is relatively limited, and research and development should seek more drugs with "multi-target" mechanisms of action

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition for treating cardiovascular diseases
  • A pharmaceutical composition for treating cardiovascular diseases
  • A pharmaceutical composition for treating cardiovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Embodiment 1, the pharmaceutical composition of the present invention is the impact on myocardial ischemia-reperfusion injury in rats

[0038] 1 drug

[0039] 1.1 Test drug preparation

[0040] Take 6ml of water for injection, heat to 80°C, add 2g of hydroxypropyl-β-cyclodextrin, stir to dissolve, add 150mg of No.1 composition, stir to dissolve No.2 composition, add 90mg of sodium chloride and stir to dissolve , and finally add water for injection to 10ml, measure the pH value of the semi-finished product (5.0-6.0), and obtain a 15mg / ml solution, and dilute in turn to obtain a 3.75mg / ml solution for later use.

[0041] Positive control drug: Xuesaitong injection, provided by Kunming Pharmaceutical Group Co., Ltd., specification: 2ml: 0.2g, spare.

[0042] 1.2 Reagents

[0043] Sodium pentobarbital was provided by Sinopharm Chemical Reagent Co., Ltd.

[0044] 0.9% sodium chloride injection, Shandong Changfu Jiejing Pharmaceutical Co., Ltd., specification 500ml / bottle...

Embodiment 2

[0074] Example 2: The effect of the combination of stilbene glycosides on the myocardial cell injury model caused by bacterial lipopolysaccharide

[0075] 1 Experimental materials

[0076] 1.1 Test sample

[0077] Preparation: After weighing an appropriate amount of tristilbene glycoside composition, add 0.01M PBS to the required volume to obtain the test product (1mg / ml); afterward, filter and sterilize through a 0.2μm filter, and dilute it with PBS in a certain proportion, Each dose of the test product was obtained separately.

[0078] 1.2 Negative control substance

[0079] Name: Sterile PBS

[0080] Source: Wuhan Boster Biotechnology Co., Ltd.

[0081] Batch number: S17B21

[0082] Specification: 500ml / bottle

[0083] Appearance: colorless liquid

[0084] 1.3 Experimental animals

[0085] Strain: SD rat

[0086] Source: Shanghai Xipuer-Bekai Laboratory Animal Co., Ltd.

[0087] Gender: male or female

[0088] Age: 1 day after birth

[0089] Animal certificate n...

Embodiment 3

[0111] Embodiment 3: the preparation of pharmaceutical composition injection of the present invention

[0112] Tristilbene, polydatin and tristilbene derivatives are prepared by weight ratio of 90% to 99% of tristilbene, 0.5% to 5% of polydatin, and 0.5% to 5% of tristilbene derivatives. Ratio, add appropriate amount of water for injection to dissolve, ultrafilter, fill, sterilize, and make injection for injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines and discloses a pharmaceutical composition for treating cardiovascular diseases. The composition comprises piceatannol 3'-O-glucoside, polydatin and a piceatannol 3'-O-glucoside derivative. Research found that the composition significantly improves the area of cerebral infarction and the area of myocardial ischemia after ischemia-reperfusion, fundamentally improves various damages caused by ischemia for patients with ischemic cardiovascular diseases, and has a good clinical application prospect.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a pharmaceutical composition for treating cardiovascular diseases. Background technique [0002] Since 2005, the overall prevalence of cardiovascular diseases in my country has been on the rise. According to the "China Cardiovascular Disease Report 2012" statistics released by the National Center for Cardiovascular Diseases, the number of patients with cardiovascular diseases in my country, including coronary heart disease, stroke, heart failure, and hypertension, is 290 million, 2 out of every 10 adults. People suffer from cardiovascular disease. Every year in my country, patients who die from cardiovascular disease account for 41% of the total death toll, ranking first among various diseases. [0003] Ischemic cardiovascular disease, also called coronary heart disease, is a common type of cardiovascular disease, and its pathological cause is myocardial ischemia. Myocardial ischemia re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7034A61P9/10
Inventor 龚云麒刘一丹陈锦锌方芳
Owner KPC PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com